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As the  second  most  common  age  related  neurodegenerative  disease  after  Alzheimer’s  disease,  the  health,
social  and  economic  impact  resulting  from  Parkinson’s  disease  will continue  to  increase  alongside  the
longevity  of the  population.  Ageing  remains  the  biggest  risk  factor  for developing  idiopathic  Parkinson’s
disease.  Although  research  into  the  mechanisms  leading  to cell  death  in  Parkinson’s  disease  has  shed  light
on many  aspects  of  the pathogenesis  of this disorder,  we  still  cannot  answer  the  fundamental  question,
what  specific  age  related  factors  predispose  some  individuals  to  develop  this  common  neurodegenera-
tive  disease.  In  this  review  we  focus  specifically  on  the  neuronal  population  associated  with  the  motor
symptoms  of Parkinson’s  disease,  the  dopaminergic  neurons  of  the substantia  nigra,  and  try to under-geing
eurodegeneration
stand  how  ageing  puts  these  neurons  at risk  to  the  extent  that  a slight  change  in protein  metabolism
or  mitochondrial  function  can  push  the  cells  over  the  edge  leading  to catastrophic  cell  death  and  many
of  the  symptoms  seen  in  Parkinson’s  disease.  We  review  the  evidence  that  ageing  is  important  for  the
development  of  Parkinson’s  disease  and  how  age related  decline  leads  to  the  loss  of  neurons  within  this
disease, before  describing  exactly  how  advancing  age  may  lead to substantia  nigra  neuronal  loss  and
Parkinson’s  disease  in  some  individuals.©  2014  The  Authors.  Published  by  Elsevier  B.V.  All rights  reserved.
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. Introduction
Parkinson’s disease (PD) affects over 1% of the population over
he age of 60, which in the UK equates to over 127,000 individ-
als (or 500,000 individuals in the USA), while in individuals over
he age of 85 this prevalence reaches 5%, highlighting the impact
hat advancing age has on the risk of developing this condition
de Lau and Breteler, 2006; Nussbaum and Ellis, 2003; Wood-
aczmar et al., 2006). Although thought of as a disease of old
ge, a small percentage of patients (about 5% of all cases) present
ith symptoms before the age of 60 years and the majority of
hese cases are caused by mutations in an ever increasing list of
enes which affect either protein metabolism or mitochondrial
unction, including Pink1 (PARK6), Parkin (PARK 2), DJ-1 (PARK7)
nd alpha-synuclein (PARK 1), thus highlighting that dysfunction
n either is sufficient to cause PD (Gasser et al., 2011). These
amilial, early onset forms of Parkinson’s disease can be autoso-
al  dominant or recessive and may  show a similar phenotype
o sporadic PD in terms of symptoms and response to L-Dopa,
ut also may  present with different symptoms and neuropathol-
gy.
Whilst Parkinson’s disease involves a complex array of symp-
oms, an important brain region affected by severe cell loss in PD,
nd the main cause of the motor symptoms associated with this dis-
rder, is the substantia nigra (SN). Specifically within the SN it is the
opaminergic neurons of the pars compacta that are lost and inter-
stingly, this brain region also shows more pathological changes
ith normal ageing than any other region (Fig. 1). A recent study
f over 750 elderly individuals (mean age 88.5 years) without clin-
cally defined PD, has shown that nearly 1/3 showed mild to severe
euronal loss within the substantia nigra, with 10% also showing
ewy body pathology (Buchman et al., 2012). Cell loss within the
N has been shown to be extensive (Rudow et al., 2008) and was
stimated to occur at a rate of 4.7% per decade (Fearnley and Lees,
991), while more recent stereological techniques estimate this
oss of neurons to occur at a rate of 9.8% per decade (Ma et al.,
999b).
Many studies have measured neuronal loss in other brain
egions with ageing, although none have shown any degree of
ell loss similar to that seen within the SN. Neuronal num-
ers have been shown to remain relatively stable throughout
ld age within the hippocampus, putamen, medial mammil-
ary nucleus, hypothalamus and the nucleus basalis of Meynert,
hile it was estimated that the neocortical neurons might show
 loss of only 10% over the entire lifespan (Pakkenberg and
undersen (1997) and reviewed in Lowe (2008)). However, in
ther dopaminergic populations including in the ventral tegmen-
al area and the retrorubral area, cell loss might actually reach
0% (Hirsch et al., 1987). These studies show that dopaminer-
ic neuronal populations seem preferentially vulnerable to loss
ith ageing compared to many other brain regions and those
elated to other neurodegenerative disorders e.g. the hippocam-
us.
An understanding of why these SN cells die with advancing age
ay  yield important insight into why cells are lost in PD. We review
he literature to define how increasing age affects the neurons of
he SN, why these cells in particular are lost and show dysfunction
ith advancing age, particularly in PD. . . . .  .  . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . .  .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  28
2. The environment of the substantia nigra
The neurons of the SN are distinct in many ways. They are pig-
mented, show pacemaking activity and increased oxidative stress
related to the metabolism of dopamine within them. They are
also thought to be particularly susceptible to the mitochondrial
dysfunction which accumulates within them with advancing age
(Bender et al., 2006; Kraytsberg et al., 2006). Here we consider the
characteristics of SN neurons which may  predispose them to an
increased sensitivity to mitochondrial dysfunction and changes in
protein degradation pathways, which may  in turn be key to the
pathogenesis of Parkinson’s disease.
2.1. Dopamine metabolism and oxidative stress
Although a significant amount of oxidative stress is generated by
the production of reactive oxygen species within mitochondria, SN
neurons are believed to be under additional oxidative stress due to
the metabolism of dopamine within them. Dopamine metabolism
by monoamine oxidase generates a number of oxidative species
including oxygen radicals and H2O2, while the oxidation of
dopamine itself might occur through a number of processes includ-
ing the presence of transition metals (reviewed in (Sulzer, 2007)).
The main protector of dopaminergic neurons against this oxida-
tive stress is the dopamine transporter (DAT). DAT takes the
damaging dopamine back into the nerve terminal where it can
then be repackaged into synaptic vesicles by VMAT2 (vesicular
monoamine transporter 2). There have been reports that DAT
expression declines with age in the dorsal tier of the SN but that
DAT staining is greatest in the ventral tier, suggesting that perhaps
this can account for some of the susceptibility of these neurons to
loss in PD compared to the population within the dorsal tier (Ma
et al., 1999a).
2.2. Calcium dynamics and pacemaking activity
Recent studies have implicated that the calcium handling of
substantia nigra neurons and the importance of calcium for their
firing activity are key to the pathogenesis of Parkinson’s disease
but also are an avenue through which to achieve neuroprotection
(Chan et al., 2007). The neurons of the SN exhibit autonomous
pacemaking activity, believed to be important for the maintenance
of dopamine levels within the striatum. In adult neurons this
activity is maintained by specific calcium channels (CaV1.3L-type)
which have recently been shown to be prevalent in other neuronal
populations which are vulnerable in PD (Goldberg et al., 2012).
However, in juvenile neurons this activity is maintained by sodium
channels and a reversion to juvenile forms of activity can be
induced in adult neurons by blockage of the calcium channels
by Isradipine. Interestingly, this reversion also protects the SN
neurons against treatment with the mitochondrial toxin rotenone,
known to cause specific SN neuronal loss and PD-like symptoms
in model systems (Chan et al., 2007).
The way in which these neurons handle calcium and the cal-
cium concentration within them is hugely important and it’s
sequestration within mitochondria is key for cellular survival.
Mitochondria are responsible for the modulation of calcium within
neurons to maintain intracellular levels, particularly important for
A. Reeve et al. / Ageing Research Reviews 14 (2014) 19–30 21
Fig. 1. Changes within SN neurons with advancing age. (A) There is an increase in the number of cells showing mitochondrial dysfunction, including a loss of key mitochondrial
proteins including complex I subunits (arrow). Changes in mitochondrial membrane potential and network dyanmics have also been shown to be important for neuronal
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otential and prior to degradation through mitophagy. There is a loss of SN neuro
espectively. The loss of neurons can be seen as a loss of pigmented cells even at a l
he maintenance of neuronal excitability. In fact, studies in neu-
ons differentiated from transmitochondrial cybrids have shown
hat neurons showing mitochondrial dysfunction show altered
esponses to multiple stimuli which leads to a prolonged elevation
f intracellular calcium (Trevelyan et al., 2010). Changes in the ATP
evels within neurons such as those that may  occur in response
o accumulating mitochondrial DNA mutations would affect the
xtrusion of calcium. This may  lead to an overload of calcium
ithin the neurons which in turn would lead to the mitochondrial
ermeability transition which then causes a loss of mitochon-
rial bioenergetic function. These events might also be initiated
y oxidative stress which as discussed previously may  occur for a
umber of reasons with advancing age within the neurons of the SN.
.3. Iron concentration and changes
The iron content of substantia nigra neurons is thought to be
n important contributor to their susceptibility to loss in PD, par-
icularly based on the generation of reactive oxygen species by
he Fenton reaction. Several studies, using various imaging tech-
iques to assess how the iron content of the SN and other deep
rain nuclei changes with advancing age, have shown that there is
n increase in the iron content of the SN with advancing age and
hat a significant increase occurs above the age of 40 within the
N pars compacta (Bilgic et al., 2012; Daugherty and Raz, 2013;
exter et al., 1989; Haacke et al., 2010; Sofic et al., 1991). However
his data remains inconclusive since other studies have reported
o change in the iron content of these neurons in PD compared to
ontrols (reviewed in Friedman et al. (2007)). This does not mean
hat the iron content of these neurons is not important. It links age-
ng to a potentially detrimental characteristic of these neurons, and
ince neuromelanin (see below) is believed to bind iron and chelate
t, again gives a plausible link between two important features ofgmentation of this network is associated with changes in mitochondrial membrane
th advancing age, images C and D show the SN of a 69 year old and a 53 year old
agnification in the SN of the 69 year old.
these neurons. The affinity of iron for melanin is much lower than
for iron binding proteins such as ferritin, however it has been shown
that neuromelanin does have a higher affinity for iron than other
melanins (Double et al., 2003; Shima et al., 1997). The mitochon-
dria, in particular a number of electron transport chain proteins,
including complex I, rely on iron sulphur clusters for their function.
Therefore changes in the concentration or availability of iron within
these neurons will additionally impact on mitochondrial function
and could thus exacerbate any mitochondrial dysfunction further,
leading to a loss of these neurons.
2.4. Neuromelanin accumulation
The pigmentation of substantia nigra is due to the accumu-
lation of neuromelanin within them. This pigment accumulates
with advancing age, is composed of many different proteins and
molecules and may  afford SN neurons with some protection against
oxidative stress. Neuromelanin begins accumulating from the 3rd
year of life and shows a progressive increase with age (Fedorow
et al., 2006; Halliday et al., 2005). It is composed of mainly lipids
but also proteins and products from the metabolism of dopamine,
explaining its distribution within very select populations of cat-
echolamine neurons within the brain (reviewed in Double et al.
(2008)). Neuromelanin is also found within other catecholamin-
ergic populations, including the neurons of the locus coeruleus,
ventral tegmental area and hypothalamus (reviewed in Double
et al. (2008)). Although this pigment accumulates within all indi-
viduals with advancing age it has been implicated to be important
for cell survival and in PD, for the vulnerability of dopaminergic
neurons. Neuromelanin has been proposed to be a free radical scav-
enger, a regulator of intracellular iron and an inactivator of cellular
cations. Therefore it is not surprising that changes in neuromelanin
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ave been implicated to be important, contributing to the selective
ulnerability of dopaminergic neurons in PD.
It has been shown that the ventral tier of the SN, which shows the
ost profound cell loss in PD, contains less neuromelanin than the
omewhat more preserved dorsal tier, suggesting that this pigment
ight have a protective effect within these neurons (Gibb and Lees,
991). Other studies have also suggested that the pigmented neu-
ons of the SN contain less neuromelanin in PD brains than in the
rain of healthy controls, again suggesting that this pigment might
rotect these neurons against intracellular stressors (Kastner et al.,
992; Zecca et al., 2001).
. Mitochondrial dysfunction within substantia nigra
eurons
The effect of mitochondrial dysfunction on the health and sur-
ival of neurons within the SN has been debated for over 3 decades,
nd although undoubtedly a contributor to the pathogenesis of PD
nd the loss of these neurons, the exact role that this organelle plays
s yet to be elucidated.
Mitochondrial dysfunction has been implicated to be important
or the pathogenesis of Parkinson’s disease since the discovery that
PP+ causes rapid parkinsonism and SN cell loss through inhibition
f complex I of the electron transport chain (Langston et al., 1983;
angston and Ballard, 1983). This discovery was followed by reports
f decreased complex I activity and protein expression in tissues
rom patients with PD (Schapira et al., 1989, 1990). The neurons
f the SN are thought to be particularly susceptible to dysfunction
ithin the mitochondria and support for a role for mitochondria,
nd specifically their dysfunction in the loss of SN neurons in PD, has
een increasing over recent years. This section reviews the data to
upport how an age related decline in mitochondrial function will
ffect cellular function and survival. Mitochondrial dysfunction is
ikely to be a key player in the loss of these neurons based on its
mpact on neuronal processes and function (reviewed in Fig. 2).
.1. Respiratory deficiency
The specific inhibition of key mitochondrial proteins including
omplex I has been known to cause Parkinsonian like symptoms
ince its inhibitors, MPP+ and rotenone, were shown to cause loss of
N neurons in both man  and model systems (Betarbet et al., 2000;
angston et al., 1983). Respiratory deficiency can be defined as a
ecline in the activity of complex IV which can be visualised in
issue using the COX/SDH assay. Bender et al. report that approx-
mately 3% of SN neurons are COX deficient in patients with PD
ompared to 1% in age matched controls, while other studies have
eported up to 30% COX deficiency in some cases (Bender et al.,
006; Itoh et al., 1996; Kraytsberg et al., 2006). Furthermore, Elson
t al. predicted that 1–4% of post mitotic cells in 80–120 year
lds would be COX deficient and that this accumulation would
egin from the age of 60 (Elson et al., 2001). The development of
espiratory deficiency within the neurons of the SN, may  also lead
o compromised production of ATP. Therefore considering recent
odelling data suggesting that the propagation of the action poten-
ial within SN neurons is highly energy dependent based on the
omplexity of the axonal arbour of these neurons, a decrease in the
roduction of ATP will affect the excitability of these neurons which
ould further increase their vulnerability (Pissadaki and Bolam,
013).
.1.1. mtDNA mutation load
The respiratory (COX) deficiency detected within the SN has
een shown to be caused specifically by mitochondrial DNA dele-
ions and these deletions were found to reach levels of 50% (Bender
t al., 2006; Kraytsberg et al., 2006). This deletion load is higher thanReviews 14 (2014) 19–30
in other brain regions and tissues where respiratory deficiency is
below 15% with even advanced age and unlike some other aged
tissues there is no accumulation of mtDNA point mutations within
the SN (Reeve et al., 2009; Taylor et al., 2003). Several studies have
compared the mtDNA deletion load between other brain regions
and the SN in both ageing and PD. Deletion levels have been found
to be higher in the SN than in the locus coeruleus, ventral tegmental
area, frontal cortex and the putamen (Bender et al., 2008; Elstner
et al., 2011). While in 1992 two  studies investigated the level of
mtDNA deletions within 12 different brain regions with advanc-
ing age. They found that in many of the brain regions studied the
level of the ‘common’ mtDNA deletion accumulated with advanc-
ing age but that the levels of this mutation were highest in the
SN followed by the basal ganglia, cortical areas and the cerebel-
lum (Corral-Debrinski et al., 1992; Soong et al., 1992). Respiratory
deficiency due to high mtDNA deletion levels is however found in
other neuronal populations in patients with Alzheimer’s disease
(AD) and multiple sclerosis (Campbell et al., 2011; Krishnan et al.,
2012). The level of mtDNA mutation and respiratory deficiency has
been shown to correlate with the cell loss seen within the cere-
bellum of patients affected by ataxia as part of their mitochondrial
disease (Lax et al., 2012). This data therefore would suggest that if
the neurons of the SN are particularly susceptible to the mitochon-
drial dysfunction shown to cause cell loss elsewhere in the brain,
then it is likely that this dysfunction is also associated with the cell
loss seen in PD.
Although there is no definitive evidence as yet to support a
mechanism for the formation of these deletions, we have hypo-
thesised that they could be formed through the repair of damage
to mitochondrial DNA (Krishnan et al., 2008). This damage leads
to the formation of double strand breaks which are then repaired
leading to the loss of several kilobases of the mitochondrial genome.
This damage could be due to a number of the processes described
above, but is likely to reflect the highly oxidative environment of
the SN. This theory has been strengthened by the work of Pickrell
et al. who specifically targeted a mitochondrial restriction enzyme,
Pst1, to the neurons of the SN. They showed that the induction
of expression of this enzyme led specifically to the formation of
double strand breaks within the mtDNA leading to deletion for-
mation and depletion, and importantly the development of motor
symptoms and SN neurodegeneration (Pickrell et al., 2011). There-
fore the formation of these mutations within human SN neurons
is likely to be a consequence of the processes mentioned above.
They then lead to reduced mitochondrial function, ATP levels and
eventually cell death. In addition mitochondrial DNA deletions have
previously been shown to cause a reduction in proteasomal activity
which could exacerbate the accumulation of misfolded protein, in
particular alpha-synuclein, as discussed below (Alemi et al., 2007).
Disruption of mitochondrial DNA integrity in mice causes an
ageing phenotype and the loss of dopaminergic neurons (Ekstrand
et al., 2007; Trifunovic et al., 2004). Initially, mice were created
with a proof reading deficient knock-in of the mtDNA polymerase,
POLG. These mice developed a premature ageing phenotype
including kyphosis, weight loss and osteoporosis, caused by an
increase in somatic mtDNA mutations, including both point muta-
tions and deletions (Trifunovic et al., 2004). This study highlighted
the importance of mitochondrial DNA for ageing and hinted that
the accumulation of defects within this genome could lead to many
of the age related changes that occur. Furthermore, a subsequent
study by the same group showed that the conditional knock-out of
the mitochondrial transcription factor A, Tfam, specifically within
dopaminergic neurons causes a reduction in mtDNA expression
and importantly progressive parkinsonism within the mice,
dopaminergic neuron loss and the accumulation of protein inclu-
sions (Ekstrand et al., 2007). The expression of mutated Twinkle
in dopaminergic neurons has shown the importance of mtDNA
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Fig. 2. Mitochondrial dysfunction has been implicated to be important for the pathogenesis of Parkinson’s disease for nearly 30 years. A number of different aspects of
mitochondrial biology have been linked to PD. This figure shows how a healthy mitochondrion (green) changes with advancing age, for example accumulating mitochondrial
DNA  deletions (shown as smaller mtDNA molecules), and becomes dysfunctional (red) and highlights key proteins and processes that have been implicated in the pathogenesis
of  PD. Mitochondrial DNA deletions lead to mitochondrial dysfunction and respiratory deficiencies and have been linked to the generation of ROS  (yellow) and the associated
oxidative stress. Changes in the expression and activity of mitochondrial electron transport chain complexes I and IV have been found in the elderly and patients with PD and
inhibition of complex I causes PD like symptoms in model systems treated with toxins such as MPTP (blue/green) and rotenone (purple). The association of the mitochondria
with  ER has been shown to be important for mitochondrial calcium handling (green) and this association relies on mitofusin 2 and DJ-1. The buffering of calcium by the
mitochondria is important for the maintenance of cellular homeostasis. Alpha-synuclein, which forms Lewy bodies, has also been shown to interact with mitochondria and
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arget  the mitochondria for degradation. These processes will all affect the survival
eletions in the survival of SN neurons and also highlighted
hanges in the expression of parkin, an important protein in the
itochondrial degradation pathway. Song et al. showed that in
lder mutant mice there was a specific loss of SN neurons which
orrelated with the development of motor defects, and that the
evelopment of the SN cell loss was related to the accumulation of
tDNA deletions. Interestingly, mutant Twinkle causes a reduction
n the expression of parkin within the midbrain and decreased pro-
easomal activity (Song et al., 2012). This evidence highlights that
isruptions of mtDNA within dopaminergic neurons are sufficient
o cause the symptoms and neuropathology associate with PD and
hus the importance of the accumulation of mitochondrial dys-
unction with advancing age to the probable pathogenesis of this
isease.
.1.2. Disruption of key mitochondrial processes
As the number of genes in which mutations are associated with
D increases so too does the evidence that changes in mitochon-
rial dynamics and turnover are important for the loss of neurons
ithin the SN. The knockout of alpha-synuclein, pink1, parkin and
J-1 in drosophila and cell culture based models leads to alterations
n mitochondrial morphology and network formation (Clark et al.,
006; Greene et al., 2003; Martin et al., 2006; Nakamura et al.,
011; Park et al., 2005, 2009). Mutations in alpha-synuclein have
een shown to cause fragmentation of the mitochondrial network
nd changes in the ultrastructure and distribution of the mitochon-
ria suggesting increased mitochondrial fission, (Nakamura et al.,
011). Mutations in Pink1 and Parkin have been shown to cause
 loss of mitochondrial ultrastructure as observed as changes in
he electron density of the mitochondria and fragmentation of the
itochondrial network (Clark et al., 2006; Greene et al., 2003). Ad in autosomal recessive forms of PD have functions important for mitochondrial
 Pink1 (indicated by ‘P’), Parkin ubiquinates a number of mitochondrial proteins to
rons in the SN with advancing age.
loss of DJ-1 causes a loss of mitochondrial membrane potential and
increased mitochondrial fragmentation (Thomas et al., 2010; Wang
et al., 2012) and mitochondrial changes have also been reported
when LRRK2 (Leucine rich repeat kinase 2) is mutated (Goo et al.,
2013; Mortiboys et al., 2010).
A recent paper has also shown that mitofusin2 (mfn2), a pro-
tein important for mitochondrial fusion, is essential for the survival
of striatal projections from the SN. Indeed knockout of mfn2 has
no effect on the number of dopaminergic SN neurons but causes
a dramatic reduction in the number of dopaminergic nerve termi-
nals in the striatum of affected mice, an accompanying reduction
in striatal dopamine levels and locomotor disturbances (Lee et al.,
2012). Mfn  2 is also a key protein for the handling of calcium within
the mitochondria, the ability of mitochondria to take up calcium
is reliant on their close proximity to the endoplasmic reticulum
(ER) and therefore the site of calcium release. The proximity of
the mitochondria to the ER is reliant on mfn2 which is enriched
at the contact sites between the ER and mitochondria (de Brito and
Scorrano, 2008). Recent evidence has also linked the expression of
DJ-1 and parkin to this interaction, DJ-1 modulates the interaction
of the mitochondria and the ER and in doing show suppresses the
effects of p53 on mitochondrial calcium handling and morphol-
ogy (Ottolini et al., 2013). Interestingly, parkin overexpression has
been shown to also enhance the calcium handling capabilities of
the mitochondria by enhancing the interaction of the mitochon-
dria with the ER without a subsequent effect on the mitochondrial
calcium uptake machinery (Cali et al., 2012). The neurons of the
SN, as mentioned above, use calcium to maintain their pacemak-
ing activity and therefore changes in how the neurons handle and
maintain calcium levels are going to be hugely influential on both
the activity and survival of these neurons.
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Both fission/fusion and mitochondrial movement require intact
itochondrial membrane potential (m) and a loss of this
otential is associated with mitochondrial degradation through
itophagy (Twig et al., 2008). Subtle differences in m have
lso been attributed to determining directionality of neuronal
itochondria, for example 80% of mitochondria with a low mem-
rane potential are transported towards the cell body (Miller and
heetz, 2004), although this might not be such a clear cut distinction
Verburg and Hollenbeck, 2008). Studies using transmitochondrial
ybrids have shown that neurons with mtDNA mutations caus-
ng a severe mitochondrial complex I defect have a significantly
ncreased m,  due to reversal of the ATP synthase, however
utations in complex IV seemed to not affect the m (Abramov
t al., 2010). The effect of these mutations on the m in these cells
s interesting considering the effect on mitochondrial protein func-
ion and expression of the accumulating mtDNA defects we see in
ged SN neurons. It has been proposed by a number of studies that
he degradation of mitochondria through the specific autophagy
athway, mitophagy, is heavily reliant on the dissipation of m,
ollowed by fission from the mitochondrial network and loss of
PA1 expression (Twig et al., 2008). Alterations in mitochondrial
ransport have been implicated to be important in a number of
eurodegenerative conditions including Alzheimer’s disease and
untington’s disease (Reddy and Shirendeb, 2012; Reddy et al.,
012). In Parkinson’s disease, alterations in mitochondrial trans-
ort occur in response to rotenone treatment and pink1 has been
hown to interact with Milton and Miro, two key proteins respon-
ible for the interaction of mitochondria with neuronal motor
roteins (Arnold et al., 2011; Weihofen et al., 2009). Therefore if
itochondria which harbour defects of the electron transport chain
o not lose their m then they will not leave the network and
ould persist within the neuron, which might explain why  neurons
ccumulate such a high proportion of dysfunctional mitochondria
ver time.
Parkin and pink1 have been implicated to be important for
he targeting of mitochondria for degradation (discussed in detail
elow). Therefore the very fact that dysfunctional mitochondria
ersist within a neuron and accumulate to a level sufficient to
ause a loss of complex IV activity and complex I protein expres-
ion would suggest that this pathway in particular shows an age
elated decline. Recent evidence suggests that the interaction of
ink1 and parkin might actually facilitate the specific turnover
f mitochondrial respiratory chain subunits (Vincow et al., 2013).
hese interactions might suggest a reason for the loss of key
ubunits of the electron transport chain, as the system might pref-
rentially target these subunits, reducing the expression of these
roteins, rather than degrading intact, yet dysfunctional mitochon-
ria. Furthermore this might lead to the accumulation of misfolded
itochondrial proteins which would put further burden onto the
rotein degradation pathways, described below.
.1.3. Interaction with alpha synuclein
The pathological hallmark of PD and other synucleinopathies
ncluding dementia with Lewy bodies (DLB), is the Lewy body. The
ain protein component of these structures is alpha synuclein,
lthough both the effect of these inclusions on neuronal survival
nd the toxicity of different forms of this protein are still debated,
t seems likely that the oligomeric forms of alpha-synuclein are the
ost toxic (reviewed in Kalia et al. (2013)). Alpha-synuclein itself is
 widely expressed protein, with an alpha helical structure (Bendor
t al., 2013), and is believed to be important for the synaptic vesi-
le recycling (Cheng et al., 2011; Murphy et al., 2000). The exact
echanism that leads to the conformational change believed to
e required for its aggregation in PD needs to be fully elucidated.
owever, what is clear is that Lewy bodies and neurites show a high
-sheet content and a distinctive cross- X-ray diffraction pattern.Reviews 14 (2014) 19–30
This pattern is interestingly also observed for fibrillar deposits in
other neurodegenerative disorders including Alzheimer’s disease,
and aggregated alpha-synuclein is strikingly similar to amyloid
(Bendor et al., 2013; Chiti and Dobson, 2006). Alpha synuclein has
also been found to aggregate in many cases of AD although inter-
estingly predominantly within the amygdala rather than the SN
(Leverenz et al., 2008; Uchikado et al., 2006). Lewy body pathol-
ogy is also seen in elderly individuals with no Parkinson’s disease
symptoms and recently we found evidence of Lewy body pathol-
ogy in a patient with POLG mutations, but with no corresponding
extrapyramidal features (Reeve et al., 2013).
Many modifications have been proposed to be important for
the aggregation of alpha-synuclein and its conformational change,
importantly these include oxidation, the presence of heavy metals
and phosphorylation (reviewed in Bendor et al. (2013)) (Breydo
et al., 2012; Fujiwara et al., 2002; Giasson et al., 2000). Accumu-
lating mtDNA mutations or dysfunctional mitochondria are likely
to have an effect on the oxidative stress levels within SN neu-
rons, which might contribute to the misfolding and accumulation
of this protein. However, in a recent study we  showed that Lewy
body pathology was  associated with neurons with intact expression
of key mitochondrial electron transport chain proteins, including
complex I, suggesting at least that intact mitochondrial function
and hence ATP levels are required for the aggregation of this pro-
tein within the cell body, perhaps relating to the transportation
of this protein (Reeve et al., 2012). Numerous studies have used
rotenone and other toxins to induce mitochondrial dysfunction and
monitor the accumulation of alpha-synuclein, despite the wealth of
information that these studies provide they often do not reflect the
subtleties of the slow accumulation of mitochondrial dysfunction
within ageing substantia nigra neurons. Our data might suggest
that normal mitochondrial function might protect against cell loss
and that those cells with mitochondrial dysfunction and Lewy body
pathology are lost, or that the accumulation of alpha-synuclein into
Lewy bodies requires mitochondrial function and that this accu-
mulation prevents toxic, damaging alpha-synuclein species from
accumulating at synapses.
Alpha-synuclein itself has been shown to interact with
mitochondria and be imported into the mitochondria in an energy
dependant manner (Devi et al., 2008). The accumulation of alpha-
synuclein within mitochondria has been shown to lead to complex
I impairment, decreased m and increased ROS production (Devi
et al., 2008; Parihar et al., 2008, 2009). The effect of these changes
is likely to be an exacerbation of the mitochondrial defect present
in ageing SN neurons. Mutations in the alpha-synuclein gene have
been shown to cause changes in mitochondrial structure particu-
larly affecting the cristae in cell culture, while drosophila models
have highlighted the contribution of oxidative stress to the neu-
ronal changes, for example showing hypersensitivity to hyperoxia
(Botella et al., 2008). Transgenic mice expressing mutant forms of
alpha synuclein have also been generated but they often do not
show SN dopaminergic neuronal loss, despite very severe pheno-
types and neuron loss in other brain regions closely associated
with inclusion formation and mitochondrial degeneration (Martin
et al., 2006). Interestingly, this neurodegeneration was  also associ-
ated with mtDNA damage and a loss of complex IV activity (Martin
et al., 2006). It is worth noting that although such models may  not
show SN pathology they often show pathology in other regions, for
example LB-like inclusions in the motor neurons of the spinal cord
(Martin et al., 2006). However, there are a number of difficulties
that arise when trying to model human disease in mice and this is
especially true for the SN, when you consider the life span of mice
and the fact that their SN neurons do not contain neuromelanin. But
these studies do highlight the close relationship and importance for
the development of neuronal loss of two  age related phenomena,
those of increased mtDNA damage and also protein accumulation.
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.1.4. PD symptoms in patients with mitochondrial disease
If mitochondrial dysfunction is particularly important in the
athogenesis of PD then we might expect to see PD symptoms
n patients with mitochondrial disorders and potentially at a
ounger age than in the case of sporadic PD. We  have shown
hat changes within the SN, and in particular cell loss within
his brain region, is more closely associated with mitochondrial
efects that are acquired rather than those that are inherited
Reeve et al., 2013). While a recent study in the POLG D257A
ouse have shown that mtDNA deletions were not associated with
N neuronal degeneration and actually induced neuroprotective
hanges including changes in the ultrastructure of the mitochon-
ria and compensatory changes in m (Perier et al., 2013).
lthough extrapyramidal features are relatively rare in patients
ith mitochondrial disorders there have been a number of reports
f Parkinsonism associated with mutations within POLG. In these
ases there is often pigmented SN neuron loss and on occasions
ewy body pathology (Betts-Henderson et al., 2009; Luoma et al.,
004) and however we have detected Lewy body pathology in
 POLG patient with no discernible cell loss or PD-like symp-
oms (Reeve et al., 2013). The age of onset of PD symptoms in
OLG patients seems to vary with many being within the range
f sporadic PD (Betts-Henderson et al., 2009; Luoma et al., 2004),
ut some cases show an earlier onset (Davidzon et al., 2006;
udson et al., 2007; Mancuso et al., 2004). Many of these ear-
ier onset cases have a family history, but they do not report
hether common PD genes were screened for mutations, there-
ore it is difficult to fully dissect whether the POLG mutation is
ausative of the PD-like symptoms. However, the incidence of
hese symptoms in patients with POLG mutations is higher than
or other mitochondrial patients and abnormal DAT scans are often
een in these patients. If the POLG mutation was  responsible for
he parkinsonism then one might expect most POLG patients to
xhibit this phenotype, many patients with POLG mutations have
ell loss within the SN, but this is not always associated with PD
ike symptoms (Reeve et al., 2013). Aside from pathogenic muta-
ions within the POLG gene, several studies have investigated the
ssociation with PD of changes within the poly-glutamine expan-
ions within the POLG1 gene in different populations (Anvret et al.,
010; Balafkan et al., 2012; Eerola et al., 2010). These studies have
hown a trend towards an association with non10-11Q repeats
nd PD in populations from Norway, America (Caucasian) and
weden (Anvret et al., 2010; Balafkan et al., 2012; Eerola et al.,
010). These cases highlight that mitochondrial dysfunction is
etrimental for the survival of SN neurons and that the accumu-
ation of mtDNA mutations affects their survival with advancing
ge. Although mutations in POLG are the most common to be
ssociated with parkinsonism in mitochondrial disease patients,
here are reports of point mutations associated with these symp-
oms (Casali et al., 2001; Horvath et al., 2007; Siciliano et al.,
001; Simon et al., 1999).
In addition, several studies have also investigated whether cer-
ain mtDNA haplogroups are associated with susceptibility for the
evelopment of PD. Many studies seem to agree that haplogroups
, K are protective against the development of Parkinson’s disease
ithin European populations, while a large study has also sug-
ested that T and super-haplogroup JT are also protective (Hudson
t al., 2013; Huerta et al., 2005; Latsoudis et al., 2008; Pyle et al.,
005; van der Walt et al., 2003). However in other populations these
aplogroups are not associated with a decreased risk of developing
D (Mehta et al., 2009). Furthermore an increased risk of developing
D with advancing age has been associated with the superhap-
ogroup HV (Hudson et al., 2013). These data highlight that even
ubtle changes within the mitochondria may  impact on the likeli-
ood of developing PD and thus be important for the pathogenesis
f this disease.Reviews 14 (2014) 19–30 25
4. Impairment of protein degradation in substantia nigra
neurons
There are two main pathways within neurons for the degrada-
tion and removal of damaged proteins, the ubiquitin proteasome
system (UPS) and autophagy, which encompasses the routes
through which substrates are degraded through the lysosome
(highlighted in Fig. 3). Both systems show a reduction in function
and efficiency with age (Jana, 2012; Li and Li, 2011; Rubinsztein
et al., 2011), are both linked to mitochondrial function since both
require ATP and alterations in both have also been implicated in the
development of both idiopathic and familial forms of PD. Although
reductions in the efficiency of these pathways with ageing are
likely to affect many populations, the SN neurons could still be
predisposed to being more severely affected by changes in these
processes.
The accumulation of damaged proteins in neurons with advanc-
ing age is related to oxidative adducts caused by reactive oxygen
and nitrogen species which, as mentioned previously, accumulate
within the SN with advancing age. Therefore the environment of
the SN predisposes the neurons to be under significant oxidative
stress with a high concentration of damaged proteins, thus effi-
cient protein degradation pathways need to be in place to cope with
an increased demand. Failure of such pathways could contribute
to the accumulation of damaging proteins such as alpha-synuclein
and could ultimately contribute to neuronal loss within this brain
region.
4.1. The ubiquitin proteasome system
The ubiquitin proteasome pathway acts to remove soluble intra-
cellular proteins. Briefly, the proteins to be degraded are covalently
linked to ubiquitin chains, which target the protein to the protea-
some, where it is unfolded and passes through the barrel of the
26S proteasome and the products of degradation are expelled at
the end. Proteolysis through the UPS is a highly energy dependent
process, requiring ATP at all stages from ubiquitination, through
proteasome assembly, and final degradation and recycling of com-
ponents. Because of this, the system is vulnerable to mitochondrial
dysfunction, through reduction of energy provision and the direct
inhibition of the proteasome through oxidised proteins and aggre-
gations thereof. In ageing there is a qualitative reduction of the
ubiquitin proteasome system (Emmanouilidou et al., 2010). In post
mortem tissue, enzymatic reactions have shown that there is a
reduction in proteasome activity in the SN of PD patients com-
pared to age matched controls (McNaught et al., 2003; McNaught
and Jenner, 2001). Moreover, mutations in Parkin known to cause
an early onset, autosomal recessive form of PD is important for the
targeting of proteins to the proteasome and expression of parkin
proteins has been shown to be reduced in PD. Furthermore, inhibi-
tion of the proteasome has been shown to cause neurodegeneration
and Lewy body like inclusions in a number of model systems while
genetic ablation of subunits of the proteasome leads to extensive
motor symptoms (Bedford et al., 2008). Conversely, mutant alpha
synuclein can cause a direct inhibitory effect on the 20S cores pro-
teolytic capabilities and the downregulation of several subunits of
the proteasome in the substantia nigra of PD patients (Chen et al.,
2005; Emmanouilidou et al., 2010; Tanaka et al., 2001).
4.2. Autophagy
Macroautophagy (hereafter autophagy) is a highly conserved
process occurring in most organisms from yeast to man, responsi-
ble for the degradation of long lived proteins and organelles. This
process requires the sequestration of the target protein within
a double membrane, the autophagosome, the delivery of the
26 A. Reeve et al. / Ageing Research Reviews 14 (2014) 19–30
Fig. 3. The degradation of proteins and organelles through the proteasome and autophagy pathways is tightly regulated and heavily ATP dependant. Both these processes
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mave  been implicated to be affected/dysregulated in Parkinson’s disease. This figure
nterconnectivity between the two  protein degradation pathways means that a de
eat  shock 70 kDa protein, DUB – deubiquitinating enzyme.
utophagosome to the lysosome, fusion with the lysosome and the
fficient degradation by lysosomal hydrolases. Although the main
egulator of autophagy is the supply of nutrients to the cell, this
ynamic process has been implicated to be important in ageing
nd a number of age related diseases, especially those involving
he accumulation of protein aggregates within neurons. Knock-out
f key autophagy related genes, ATG 5 and 7, has been shown to
ause neurodegeneration in mice, particularly a loss of the Purkinje
ells of the cerebellum (Hara et al., 2006; Komatsu et al., 2006).
The degradation of whole mitochondria occurs through the
pecific autophagy pathway, mitophagy. A number of genes that
ave been shown to cause familial autosomal-recessive forms of
arkinson’s disease are known to be important for the targeting
f mitochondria to this pathway, such as Parkin and Pink1. The
ecruitment of parkin, a ubiquitin E3 ligase, to damaged mitochon-
ria requires the function of the putative kinase, Pink1. In addition,
ccumulation of autophagosomes has been found in PD brains
eflecting the decrease in successful clearance in this disease
Anglade et al., 1997). This observation suggests that perhaps
he autophagy pathway becomes overwhelmed, or that there is
n over production of autophagosomes, perhaps in response to
he accumulating dysfunctional mitochondria. Alternatively, an
ccumulation of these ‘end stage’ vesicles may  actually represent
 decrease in autophagy and autophagic flux (Ma  et al., 2012; Zhou
t al., 2012). The pathway by which mitochondria are degraded
hrough autophagy is a tightly regulated process, which in theory
hould degrade dysfunctional mitochondria preventing their age
ssociated accumulation. Recent mouse studies have shown that
ysfunctional mitochondria do not necessarily recruit parkin and
hat in fact the absence of parkin may  not affect the phenotype or
learance of mitochondria (Sterky et al., 2011). One of the other
roposed substrates for Parkin is alpha-synuclein. Although usu-
lly degraded through the proteasome, alpha-synuclein requires
nfolding for degradation and aggregating forms of this protein
ay  require clearance through other pathways. Alpha-synuclein,ws how these pathways are affected and the mechanism for their dysfunction. The
 in the efficiency of one will strongly impact on the burden of the other. HSC70 –
however, is also a target for chaperone mediated autophagy, which
through interactions with LAMP-2A and HSC (heat shock 70 kDa
proteins) targets the alpha-synuclein directly to the lysosome
(Alvarez-Erviti et al., 2010, 2013; Vogiatzi et al., 2008).
Clearly one of the most relevant relationships is that of the
protein degradation pathways and their degradation of alpha-
synuclein. This protein has been shown to be ubiquitinated for
degradation through the proteasome, as well as degraded through
chaperone mediated autophagy. Mutated forms of alpha-synuclein
can bind to the lysosomal membrane without translocation
through interactions with Lamp-2A, essentially blocking their own,
and other substrates degradation through this pathway. Consid-
ering that the pathological hallmark of Parkinson’s disease is the
accumulation of Lewy body structures, it would seem only log-
ical that the systems within the cell designed to remove these
damaging forms of alpha-synuclein might show reduced efficiency.
Similarly, the observation that neurons within the SN accumulate
dysfunctional mitochondria would imply that with ageing the effi-
ciency of mitophagy declines as damage to the mitochondria and
mtDNA increases. Alongside these observations are investigations
into changes in the expression of deubiquitinating enzymes (DUBs).
DUBs act as a signal for both proteasomal and lysosomal degra-
dation of proteins, and provide a scaffold for signal transduction.
Their accumulation has been shown to occur within LBs suggesting
that one cause of the accumulation of alpha-synuclein into these
structures may be impaired autophagic flux (Tanaka et al., 2001).
5. Comparison with other neuronal populations that are
vulnerable in PD
The neurons of the SN are not the only ones to be affected
in PD (Braak et al., 2004; Del Tredici and Braak, 2012), do these
other neuronal populations show any similarities with the neu-
rons of the SN? Changes have been reported to also occur in several
other brain stem nuclei including; the pedunculopontine nucleus
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Fig. 4. Age related changes in a number of processes pushes substantia nigra neurons towards cell death. These changes include accumulation of mitochondrial DNA defects,
oxidative damage (through a number of processes) and accumulation of neuromelanin. This increases the vulnerability of the SN neurons so that a further insult from either
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egion. Several of these processes have been shown to be sufficient to cause substan
n  Parkinson’s disease.
PPN), ventral tegmental area (VTA), the dorsal motor nucleus of
he vagus nerve (DMV) and the locus coeruleus (LC). These neu-
onal populations show similarities with the neurons of the SN
hich may  highlight not only their vulnerability in PD but also
he processes key for the loss of SN neurons (Surmeier and Sulzer,
013). The medium sized neurons of the LC, for example, con-
ain neuromelanin, are noradrenaline containing, TH positive and
how a loss of around 70% in PD (Gesi et al., 2000). These neurons
how alterations in the ultrastructure of their synaptic mitochon-
ria in PD, suggesting mitochondrial alterations might occur within
hese neurons (Baloyannis et al., 2006). There is also a reduction
n the large cholinergic neurons of the PPN, 50% of these neu-
ons have been reported to be lost in PD (reviewed in (Pahapill
nd Lozano, 2000)). Interestingly LB pathology has been found in
hese neurons in both Lewy body disease (LBD) and Alzheimer’s dis-
ase, but prominent cell loss was only found in LBD (Dugger et al.,
012).
The cholinergic neurons of the DMV  show Lewy body pathology
n patients with PD at Braak stage 1, while pathology only appears in
he SN at stage 3 (Braak et al., 2004). The vulnerability of this group
f neurons in PD has recently been investigated. These neurons
lso rely on pacemaking activity, similar to the neurons of the SN.
 major contributor to this activity within the neurons of the DMV
re the L-type CaV1.3 channels and similar to the SN neurons DMV
eurons show evidence of mitochondrial stress during pacemak-
ng activity (Goldberg et al., 2012). Furthermore, the dopaminergic
eurons of the VTA also show pacemaking activity, but the activity
n these neurons is modulated primarily by sodium with minimal
ontribution from calcium channels (Khaliq and Bean, 2010). It is
herefore interesting that in comparison to the neurons of the SN
he VTA neurons are relatively spared, in addition the neurons of the
TA have been shown to be resistant to the overexpression of alpha-
ynuclein, known to cause the loss of SN neurons (Maingay et al.,
006). The development of LB pathology in a number of other brain
tem nuclei has also been investigated and interestingly within this
roup of nuclei only those which show an accumulation of lipofus-
in or neuromelanin show an increased likelihood of developing
his pathology (Braak et al., 1995, 2001).Therefore vulnerable neuronal populations show some charac-
eristics which are common to those of SN neurons, suggesting that
he unique mixture of these features within the SN contributes
ignificantly to the development of PD.lation of all these processes that will lead to the loss of neurons within this brain
ra neuronal loss alone and so are likely to contribute to the death of these neurons
6. Conclusion
With advancing age a number of processes essential for the func-
tion of substantia nigra neurons including dopamine metabolism,
wild type mitochondrial DNA copy number and protein degrada-
tion decline (Fig. 4). Dopamine metabolism generates a significant
amount of reactive oxygen species that will affect a number of dif-
ferent processes within the neurons, a decline in wild type mtDNA
copy number will lead to a decrease in ATP production and a reduc-
tion in efficient protein degradation will affect the functioning of
neurons. In addition accumulation of neuromelanin, the ability of
neurons and mitochondria to handle calcium and the levels of iron
within these neurons will also be affected, so that additional insults
such as mitochondrial complex I and IV deficiencies and aggre-
gating alpha-synuclein causes the loss of vulnerable neurons, once
this cell loss reaches a certain level, the symptoms of PD develop.
Any minor changes that affect this vulnerability to accumulating
damage may  explain why  not all individuals are affected by PD
with advancing age. In isolation some of these processes including
mitochondrial DNA mutations and changes in protein degradation
pathways have been shown to cause neuronal loss (Hara et al.,
2006; Komatsu et al., 2006; Reeve et al., 2013), but with advancing
age it is the accumulation of many defects that renders the neu-
rons of the SN vulnerable to the additional insults of mitochondrial
deficiencies and toxic alpha-synuclein species.
Therefore, in conclusion we believe that ageing effects cause a
cascade of stressors within the substantia nigra which essentially
weakens the neurons and their ability to respond to further insults
that are seen as part of the disease process. Further mitochondrial
dysfunction and alterations in protein degradation pathways are
subsequently far more detrimental to the neurons of the SN than
they would be to neurons elsewhere within the brain.
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